Holen Sie sich die Stockscreener-App
15.35
1.18%
-0.165
Schlusskurs vom Vortag:
$15.51
Offen:
$15.44
24-Stunden-Volumen:
51,287
Relative Volume:
0.28
Marktkapitalisierung:
$984.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-15.25
EPS:
-1.0062
Netto-Cashflow:
-
1W Leistung:
+10.63%
1M Leistung:
+15.42%
6M Leistung:
+74.38%
1J Leistung:
+791.15%
1-Tages-Spanne:
$15.26
$15.94
1-Wochen-Bereich:
$13.78
$16.12
52-Wochen-Spanne:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Firmenname
Adlai Nortye Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare ANL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
15.29 | 998.81M | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.28 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Aktie (ANL) Neueste Nachrichten
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - Investing.com
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com India
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
ANL Stock Price, Quote & Chart | ADLAI NORTYE LTD-ADR (NASDAQ:ANL) - ChartMill
Adlai Nortye initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Adlai Nortye stock coverage with Outperform By Investing.com - Investing.com Nigeria
Oppenheimer initiates Adlai Nortye stock coverage with Outperform - Investing.com
ANL - Finviz
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's what you should know - MSN
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Adlai Nortye CEO Lu Yang sells $131 in company stock By Investing.com - Investing.com Australia
Adlai Nortye CEO Lu Yang sells $131 in company stock - Investing.com
Adlai Nortye initiated with a Buy at JonesResearch - TipRanks
Finanzdaten der Adlai Nortye Ltd Adr-Aktie (ANL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):